(Q40481236)

English

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Michael J Grace

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Seoju Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sheri Bradshaw

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jeffrey Chapman

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jeffrey Spond

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Stuart Cox

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Marc Delorenzo

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Diana Brassard

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

David Wylie

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Susan Cannon-Carlson

10

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Constance Cullen

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Stephen Indelicato

12

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Marcio Voloch

13

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Ronald Bordens

14

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

13 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

280

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

6327-6336

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Pegylated interferons for the treatment of chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Structure, biology, and therapeutic implications of pegylated interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Objective antiviral assay of the interferons by computer assisted data collection and analysis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Development of pegylated interferons for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Antiviral actions of interferons

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

The state of the STATs: recent developments in the study of signal transduction to the nucleus

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

How cells respond to interferons

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

A species of human alpha interferon that lacks the ability to boost human natural killer activity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Human IFN-alpha protein engineering: the amino acid residues at positions 86 and 90 are important for antiproliferative activity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Differential responsiveness of a splice variant of the human type I interferon receptor to interferons.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412134200

21 January 2018

Identifiers

10.1074/JBC.M412134200

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40481236&oldid=1525260473"